Skip to content

Hypnotherapy With Audiofiles for Children and Adolescents With Disorders of Gut-brain Interactions in Sweden -a Feasibility Study

Hypnotherapy With Audiofiles for Children and Adolescents With Disorders of Gut-brain Interactions in Sweden -a Feasibility Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06493097
Enrollment
32
Registered
2024-07-09
Start date
2023-10-01
Completion date
2024-08-30
Last updated
2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Abdominal Pain Syndrome, Functional Bowel Disorder, Self-hypnosis

Brief summary

This study aims at testing the effect and feasibility of a new treatment strategy - hypnotherapy mediated with audio files - for children and adolescents with disorders of gut-brain-interaction (DGBI) in Sweden. The treatment protocol has been used and studied in Netherlands, but the investigators have translated and formed it to suit the Swedish population. This study is a feasibility study that is followed by a large RCT to compare different psychological treatment options for this patient group. If hypnotherapy mediated via audio files proves to be effective and feasible for this patient group, it would mean: 1. An exponential increase in the availability of evidence-based treatments. The hypnotherapy treatment is markedly easier to distribute than e.g. cognitive behavior therapy (CBT) which requires chat contact with a psychologist and is made available regardless of where in Sweden the family lives. In addition to shortened waiting times for patients, this would decrease the pressure in somatic care. 2. Possibility to offer tailored treatments. No treatment works for everyone. It is reasonable to assume that treatments with such different focuses as hypnotherapy and exposure-based CBT may be differently effective for different patients. A new treatment option can help a larger proportion of patients. 3. A more cost-effective treatment. Gut-directed hypnotherapy with audio files is a very inexpensive treatment, which would likely result in significant cost savings for this patient population.

Detailed description

Hypnotherapy has shown promising results in international studies for treatment of DGBI. Gut-directed hypnotherapy for children is based on relaxation and imagery and sensation exercises with a focus on gastrointestinal symptoms ("directed daydreams", which both divert and provide a pleasant feeling in the body, which the child can use when the symptoms come). The aim is to both improve awareness of and increase control over the symptoms. Hypnotherapy is a safe treatment that has been shown to have minimal side effects. The research group in the Netherlands with whom investigators collaborate in this project has shown a significantly better effect in short and long term with hypnotherapy than with conventional medical treatment for children and adolescents with DGBI. Hypnotherapy via home-based self-exercises with audio files is proven as effective as individual therapy performed face-to-face by a therapist. Preliminary results/ backround work: Collaboration with the Dutch group started, the treatment manual for gut-directed hypnotherapy has been translated into Swedish and has undergone cultural validation by experienced child psychologists and has been recorded in audiobook quality. The study website (where the families have access to the treatments and measure the outcomes) has been created. Comprehensive patient information material has been created about DGBI and hypnotherapy, which consists of both texts, films, and audio to reach all patient types (Fig 1a-b). The pilot study is ongoing since Sep 2023. Aim: To test the practical aspects concerning patient recruitment, information about treatment, the treatment itself, measurement of outcome, required power for the main outcome. The lessons learned will help investigators to fine-tune the protocol and give the planned large RCT optimal conditions. Study population: 30 patients (8-17 years, of which approximately half are 13-17 years) from Sachsska Children's Hospital's Gastrointestinal Clinic and Pediatric and Adolescent Medical Clinics in Stockholm, who are diagnosed with DGBI following Rome IV criteria. Before inclusion, the families meet with a study physician and a study nurse for an assessment of inclusion and exclusion criteria, for information about the study, and review of treatment principles. Exposure: Gut-directed hypnotherapy exercises 5 times/week, for 12 weeks, delivered via audio files on the study's website (files can also be downloaded to mobile phone). Outcome: At the beginning and end of the treatment and every third week during the treatment, the patients and parents will fill in self-assessments in the form of internationally validated questionnaires for symptom severity, quality of life, school absence etc, via an internet platform with identification control (which we have worked with in many previous projects). Improvement by \>30% on the primary outcome measure is defined as clinically significant, based on international recommendations. Power: In several previous pilot studies, 30 patients have been sufficient to obtain meaningfully tight confidence intervals for the outcome measures and to be able to conclude for future RCTs. However, no formal power analysis is relevant without a comparison group.

Interventions

BEHAVIORALGut-directed hypnotherapy via audio files

5 audio files 10-15 min each, min 5 times a week for 12 weeks

Sponsors

Karolinska Institutet
Lead SponsorOTHER
Region Stockholm
CollaboratorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis: irritable bowel syndrome, functional abdominal pain, functional dyspepsia (following the Rome IV diagnostic criteria) * The participant and at least one of the parents must understand Swedish

Exclusion criteria

* other medical condition that better explains the symtoms * Absence from school \>40% and/or psychiatric diagnosis that is judged to be more primary than the gastrointestinal problems, in these cases the children/young people are judged to need more intensive and multi-professional treatment

Design outcomes

Primary

MeasureTime frameDescription
Peds-QL-gastroWeek 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.Short questionnaire gastrointestinal symptom scale. Minimum value 0, maximum value 100, higher score means better outcome.

Secondary

MeasureTime frameDescription
Pain Frequency and IntensityWeek 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.FACES pain scale. Minimum value 0, maximum value 10, higher score means worse outcome.
StressWeek 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.PAS pediatric stress questionnare. Minimum value 0, maximum value 44, higher score means worse outcome.
Gastrointestinal Symtom -Related AnxietyWeek 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.BRQ-C questionnare. Minimum value 11, maximum value 77, higher score means worse outcome.
GI Symptom Specific AnxietyWeek 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.Visceral sensitivity index short scale. Minimum value 0, maximum value 35, higher score means worse outcome.
Quality of LifeWeek 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.Peds-QL- QOL. Minimum value 0, maximum value 100, higher score means better outcome.
Adequate ReliefWeek 12 (post) treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.SAQ. Minimum value 0, maximum value 7, higher score means better outcome.

Countries

Sweden

Contacts

PRINCIPAL_INVESTIGATOROla Olén, MD PhD prof

Department of clinical epidemiology, Karolinska Institutet

Participant flow

Recruitment details

Children and adolescents with DGBI aged 8-17 years at the start of the treatment were recruited from Sachs Children's Hospital and four outpatient pediatric clinics in Stockholm between October 2023 and June 2024.

Pre-assignment details

Participants received the intervention within 4 weeks from enrollment, all participants received same intervention in this pilot study.

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
32 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Diagnosis FAP-NOS (functional abdominal pain - not otherwise specified)5 Participants
Diagnosis FD (functional dyspepsia)5 Participants
Diagnosis IBS (irritable bowel syndrome)22 Participants
Region of Enrollment
Sweden
32 Participants
Sex: Female, Male
Female
22 Participants
Sex: Female, Male
Male
10 Participants
Symtom duration >2 years24 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 32
other
Total, other adverse events
0 / 32
serious
Total, serious adverse events
0 / 32

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026